Pressmeddelande -

SPAGO Imaging appoints Eva Redhe Ridderstad as Chairman

SPAGO Imaging AB appoints Eva Redhe Ridderstad as Chairman of the Board prior to the planned IPO and spin-off from Accelerator.  

Eva Redhe Ridderstad, today Board Member of Probi AB and Accelerator’s former subsidiary PledPharma AB, has long experience from leading positions in public companies and has previously been both CEO and Chairman of Erik Penser Fondkommission AB and Board Member of Q-Med AB. 

”Eva Redhe Ridderstad has many years of board experience in public companies.  She is a valuable addition as Chairman of the Board of SPAGO, especially given the planned IPO and spin-off from Accelerator”, says Maria Wrethag, CEO Accelerator Nordic AB. 

Eva Redhe Ridderstad will be formally appointed as Chariman of the Board of SPAGO Imaging AB 12 November 2012. 

As previously communicated, the Board of Accelerator Nordic AB (“Accelerator”) has decided to prepare for an IPO and spin-off of Accelerator’s subsidiary SPAGO Imaging AB (“SPAGO”). The formal decision regarding the proposed dividend of Accelerator’s holdings in SPAGO to Accelerator’s shareholders is expected to be taken at Accelerator’s annual general meeting 2013. 

As also previously communicated, the Board of SPAGO plans to conduct a share issue of 21 MSEK in connection with the planned listing of the company at AktieTorget in Q4 2012. Priority will be given to shareholders of Accelerator Nordic AB and specially invited external investors. The share issue will primarily fund the final studies needed to take the company’s main project to clinical trials. 

For additional information, please contact Maria Wrethag, CEO Accelerator Nordic AB, +46 76 119 1983.

Ämnen

  • Ekonomi, finans

Kategorier

  • accelerator
  • spago
  • eva redhe ridderstad
  • chairman
  • maria wrethag

Regioner

  • Skåne

SPAGO Imaging AB develops a nanoparticle based, tumor selective MRI contrast agent, SPAGO Pix, that has the potential to significantly improve tumor diagnostics with MRI (Magnetic Resonance Imaging). SPAGO Pix is designed to better visualize small soft tissue tumors with increased specificity, i.e. fewer “false positive” results, thus enabling earlier onset of cancer therapy as well as avoidance of unmotivated or unnecessary treatment. For more information, please visit, www.spagoimaging.se.

Accelerator Nordic AB is a group of Life Science companies focused on Imaging Software and Medical Nanotechnology. Accelerator’s subsidiaries have exposure towards large growth markets such as oncology, orthopedics, and diagnostics. Accelerator Nordic is publicly traded on the Aktietorget exchange in Stockholm, Sweden. For more information please visit, www.acceleratorab.se.

Kontakter

Relaterat innehåll

  • Nyemission i SPAGO Imaging AB (publ) om 21 miljoner kronor

    Som tidigare meddelats, avser styrelsen i SPAGO Imaging AB (publ) att, i samband med den planerade listningen av bolaget, genomföra en riktad nyemission om 21 miljoner kronor, med förtur för aktieägare i Accelerator Nordic AB samt särskilt inbjudna externa investerare. Nyemissionen ska i huvudsak finansiera arbetet att ta bolaget fram till kliniska studier och ut-licensiering.

  • VD Maria Wrethag kommenterar avknoppning av SPAGO och renodlingen av Accelerator

    I ett tidigare pressmeddelande 2 oktober 2012 meddelandes att styrelsen i Accelerator har beslutat förbereda för en separatnotering av dotterbolaget SPAGO Imaging AB samt en utdelning av Accelerators innehav i SPAGO till befintliga aktieägare i Accelerator samt att SPAGO Imaging AB avser genomföra en nyemission om 21 miljoner kronor under 2012. Läs VDs kommentarer i detta pressmeddelande.

  • Avknoppning av SPAGO - Unikt MR-kontrastmedel för väsentligt förbättrad tumördiagnostik

    Styrelsen i Accelerator Nordic AB har beslutat att förbereda för en separatnotering av SPAGO Imaging AB samt en utdelning av Accelerators innehav i SPAGO Imaging AB till befintliga aktieägare i Accelerator. SPAGO Imaging AB avser även att genomföra en nyemission om 21 miljoner kronor under 2012 för att finansiera den fortsatta utvecklingen. Läs mer i detta samt efterföljande pressmeddelande.